Insmed Hit Operating Breakeven. The Market Is Still Pricing a Cash Incinerator.

Insmed hit operating breakeven in the second quarter. A $1.5 million operating loss on Total Company Revenues of $425.5 Million for the Second Quarter of 2026 is the closest this company has come to running a balanced sheet since it started burning through cash to build its pipeline. The stock is still priced as if that cash burn isn't going anywhere.

The market remembers the old story. Brensocatib failed a Phase 2 trial in chronic rhinosinusitis last December — one analyst called it the "worst-case scenario for the program". The stock was down 53% from its 2025 peak. FCF for the trailing twelve months sits at -$808 million. Operating margins are negative by any measure. The old story is a biotech that spent billions building a pipeline, launched a drug, and is still hemorrhaging money.

But Q2 2026 changes the shape of the problem.

The Proof Point

BRINSUPRI® (brensocatib) Revenues of $309.2 Million for the Second Quarter of 2026, Reflecting 49% Growth Over the First Quarter of 2026. That acceleration is faster than the market was forecasting. Insmed raised its full-year 2026 BRINSUPRI guidance from "at least $1 billion" to $1.25–$1.4 billion. The company now expects combined peak sales across its three lead programs — BRINSUPRI, ARIKAYCE, and the pipeline asset TPIP — to exceed $14 billion, with BRINSUPRI alone topping $7 billion.

Meanwhile, the operating losses collapsed. Q2 2025 saw a $312.9 million operating loss. Q2 2026 delivered essentially breakeven at $1.5 million. Net loss fell to $13.2 million ($0.06 per share) versus consensus expectations of -$0.69 per share. That's a nearly nine-times EPS beat, the kind of number that doesn't happen unless the trajectory has genuinely shifted.

Here's why: BRINSUPRI carries an 81.8% gross margin — significantly higher than ARIKAYCE's. As BRINSUPRI displaces ARIKAYCE as the revenue driver, the blended cost of goods falls. Operating expenses (R&D plus SG&A) are still elevated at roughly $457 million in Q2, but they're not growing at the same pace as revenue. The math is simple. Revenue is doubling; fixed operating costs are rising incrementally. That is operating leverage in action, not a one-off accounting quirk.

The cash position remains intact. Insmed held approximately $545 million in cash and equivalents at the end of Q2, with total cash and marketable securities at roughly $1.2 billion. Against $1.3 billion in total debt, net debt is negative by about $617 million. The liquidity runway is not the concern it was.

What the Market Is Still Anchored To

As of August 5th, Insmed's stock closed at $99.02. Today it's back toward $128, up nearly 30% in five days on the Q2 print. But the market cap of $27.9 billion still prices this company at 24.6 times trailing sales. That looks expensive until you realize the "trailing" revenue base of $1.14 billion is a phantom number — it includes two quarters from 2025 when BRINSUPRI hadn't launched yet. Full-year 2026 revenue is heading toward $1.7–$1.9 billion at the guided midpoint. On that forward revenue base, the effective multiple is closer to 15x.

That's still not cheap. But the comparison matters. The industry P/S average sits at 10.9x, peer average at 6.5x — but those peers aren't growing revenue at 186% year-over-year and approaching operating breakeven in their second quarter of meaningful product sales. The fair P/S multiple for Insmed's growth profile is estimated at roughly 19.7x by model-based frameworks, implying the stock isn't wildly rich once you account for the trajectory.

AInvest's aggregate signal still labels Insmed a Buy, which is consistent with the institutional view that the BRINSUPRI launch momentum outweighs the valuation headline. But the signal doesn't capture the speed at which the operating loss has collapsed. That's the piece the market has yet to fully absorb.

The Rerating Bridge

Simple forward multiples beat complex DCF models. Here's the bridge.

If BRINSUPRI hits the $1.3 billion midpoint of updated 2026 guidance and ARIKAYCE comes in at $460 million (middle of range), total revenue sits at roughly $1.76 billion. If operating expenses grow at half the pace of revenue — a conservative assumption given that Q2 already showed the inflection — operating income for the back half of the year could land somewhere between $100–$200 million. Even at the low end, annualized operating income of $200–$400 million is a step function away from the -$808 million FCF run rate the market has been anchoring to.

That's the proof path. Not a pipeline optionality argument. Not a "TPIP might work someday" story. The operating leverage is real, it just showed up, and the market is still quoting the trailing multiple from a revenue base that no longer exists.

If Insmed can sustain even a modest positive operating income in 2027 while BRINSUPRI expands internationally (the UK approved it in February, Japan is anticipated later this year), the rerating mechanism is straightforward. Revenue of $2–$2.5 billion with operating margins expanding past 10% would justify a $10–$15 billion operating income multiple — a $20–$30 billion market cap at today's levels and a clear step up from the old narrative.

What Could Still Break It

The CRS failure in December isn't a total write-off of the molecule's immunology potential — management is advancing INS1033, a second DPP1 inhibitor, toward IND filing in H2 2026 for rheumatoid arthritis and IBD. But it does mean BRINSUPRI carries the weight of the near-term thesis alone. If U.S. adoption stalls — if prescriber uptake slows, if reimbursement headwinds intensify, if the sequential growth rate decelerates from 49% to something modest — the operating leverage story compresses.

TPIP remains unproven. Phase 3 in pulmonary arterial hypertension started in April; Phase 3 in pulmonary fibrosis is expected later this year. The $6 billion peak revenue estimate for TPIP is a pipeline optionality bet, not current evidence. It's worth the mention because it supports the valuation premium, but it shouldn't be the foundation of the thesis.

And the trailing FCF number won't look clean until the burn actually turns positive on a rolling basis. A single quarter near breakeven is encouraging, but it takes three or four to prove the trend isn't a seasonal artifact.

The Setup

This is what the setup looks like. Expectations have reset — the stock is well below its peak, the CRS failure is in the rearview, Mizuho lowered its price target on Insmed shares to $192 from $202 — while the operating numbers are pointing in the opposite direction. Revenue accelerating, losses collapsing, guidance being raised, cash position intact.

I'm not asking for perfection here. I'm asking for the next two quarters to confirm the trajectory. If Q3 shows another sequential jump in BRINSUPRI revenue and the operating loss stays compressed — or turns positive — the rerating has legs. If Q3 revenue growth decelerates materially and the operating loss re-widens, the thesis is stale.

Discipline over ego. The market is still pricing the old story. The numbers already say something different.

Tripwire: BRINSUPRI sequential revenue growth falling below 15%, or Q3 operating loss widening back past $100 million. Either of those signals the leverage story is broken and the cash-burner narrative is back in charge.